Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2015 | Oct. 25, 2016 | Jun. 30, 2015 | |
Document and Entity Information: | |||
Entity Registrant Name | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2015 | ||
Trading Symbol | tsoi | ||
Amendment Flag | false | ||
Entity Central Index Key | 1,419,051 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Common Stock, Shares Outstanding | 740,251,000 | ||
Entity Public Float | $ 389,268 | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Document Fiscal Year Focus | 2,015 | ||
Document Fiscal Period Focus | FY |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Current assets: | ||
Cash and cash equivalents | $ 2,183 | $ 2,894 |
Accounts Receivable, net | 2,184 | 0 |
Inventories | 29,675 | 0 |
Prepaid expenses and other current assets | 213,444 | 139,016 |
Assets from discontinued operations | 0 | 46,845 |
Total current assets | 247,488 | 188,756 |
Other non-current assets | 12,476 | 12,461 |
Property and equipment, net | 0 | 0 |
Total assets | 259,964 | 201,217 |
Current liabilities: | ||
Accounts payable | 277,342 | 290,554 |
Accrued expenses and other current liabilities | 15,636 | 14,777 |
Due to related parties | 196,014 | 27,174 |
Total current liabilities | 488,992 | 332,505 |
Shareholders' Equity | ||
Preferred stock, $.001 par value; 5,000,000 shares authorized | 0 | 0 |
Common stock, $.001 par value; 699,999,999 shares authorized, 541,000,000 issued and outstanding at December 31, 2015 and 699,999,999 shares authorized, 400,000,000 issued and outstanding at December 31, 2014 | 541,000 | 400,000 |
Capital in excess of par | 2,440,709 | 2,093,009 |
Deficit accumulated | (3,210,737) | (2,624,296) |
Total shareholders' equity | (229,028) | (131,288) |
Total liabilities and shareholders' equity | $ 259,964 | $ 201,217 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets Parentheticals - $ / shares | Dec. 31, 2015 | Dec. 31, 2014 |
Parentheticals | ||
Preferred Stock, par value | $ 0.001 | $ 0.001 |
Preferred Stock, shares authorized | 5,000,000 | 5,000,000 |
Common Stock, par value | $ 0.001 | $ 0.001 |
Common Stock, shares authorized | 699,999,999 | 699,999,999 |
Common Stock, shares issued | 541,000,000 | 400,000,000 |
Common Stock, shares outstanding | 541,000,000 | 400,000,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Audited) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Revenues: | ||
Net Sales | $ 1,911 | $ 0 |
Cost of Goods Sold | 3,193 | 0 |
Gross Profit | (1,282) | 0 |
Operating expenses: | ||
General and administrative | 73,353 | 50,868 |
Salaries, wages, and related costs | 266,286 | 111,986 |
Selling expenses | 3,894 | 0 |
Amortization and depreciation | 0 | 21,133 |
Consulting fees | 185,700 | 39,734 |
Legal and professional fees | 40,420 | 103,384 |
Total operating expenses | 569,653 | 327,105 |
Loss from operations | (570,935) | (327,105) |
Other income (expense): | ||
Net other income (expense) | 3,866 | 8,728 |
Impairment of intangible asset | 0 | (210,000) |
Interest expense | (5,550) | (9,375) |
Total other income (expense) | (1,684) | (210,647) |
Net income (loss) from continuing operations | (572,619) | (537,752) |
Net income (loss) from discontinued operations | (13,822) | 249,002 |
Net income (loss) | $ (586,441) | $ (288,750) |
Basic and diluted loss per common share | ||
Continuing operation | $ 0 | $ 0 |
Discontinued operation. | $ 0 | $ 0 |
Weighted average shares outstanding | 461,967,123 | 196,385,920 |
Condensed Consolidated Stateme5
Condensed Consolidated Statement of Changes in Shareholders' (Deficit) (Audited) - USD ($) | Common Stock | Common Stock Amount | Additional Paid-in Capital | Earnings (Deficit) Accumulated | Total |
Balance at Dec. 31, 2013 | 94,466,400 | 94,466 | 1,665,725 | (2,335,546) | (575,355) |
Stock issued for service on March 31, 2014 | 12,000,000 | 12,000 | 33,750 | 45,750 | |
Stock issued for note conversion on June 30, 2014 | 90,000,000 | 90,000 | 180,000 | 270,000 | |
Stock issued for note conversion on September 30, 2014 | 103,533,600 | 103,534 | 103,534 | 207,067 | |
Stock issued for a material definitive agreement | 100,000,000 | 100,000 | 110,000 | 210,000 | |
Net Loss, December 31, 2014 | $ (288,750) | $ (288,750) | |||
Balance. at Dec. 31, 2014 | 400,000,000 | 400,000 | 2,093,009 | (2,624,296) | (131,288) |
Stock issued on March 27, 2015 | 20,000,000 | 20,000 | 30,000 | 50,000 | |
Stock issued on April 17, 2015 | 20,000,000 | 20,000 | 30,000 | 50,000 | |
Stock issued on June 8, 2015 | 1,000,000 | 1,000 | 1,500 | 2,500 | |
Stock issued on July 15, 2015 | 1,000,000 | 1,000 | 1,500 | 2,500 | |
Stock issued on August 31, 2015 | 10,000,000 | 10,000 | 15,000 | 25,000 | |
Stock issued on October 14, 2015 | 2,000,000 | 2,000 | 3,000 | 5,000 | |
Stock issued on October 16, 2015 | 4,000,000 | 4,000 | 6,000 | 10,000 | |
Stock issued on November 9, 2015 | 3,000,000 | 3,000 | 4,500 | 7,500 | |
Stock issued on November 23, 2015 | 20,000,000 | 20,000 | 30,000 | 50,000 | |
Stock issued for services on February 27, 2015 | 2,000,000 | 2,000 | 3,000 | 5,000 | |
Stock issued for services on April 1, 2015 | 10,000,000 | 10,000 | 15,000 | 25,000 | |
Stock issued for services on June 1, 2015 | 7,000,000 | 7,000 | 10,500 | 17,500 | |
Stock issued for services on June 1, 2015 | 3,000,000 | 3,000 | 4,800 | 7,800 | |
Stock issued for services on September 25, 2015 | 10,000,000 | 10,000 | 36,000 | 46,000 | |
Stock issued for services on October 1, 2015 | 23,000,000 | 23,000 | 121,900 | 144,900 | |
Stock issued for services on October 13, 2015 | 2,500,000 | 2,500 | 12,500 | 15,000 | |
Stock issued for services on November 30, 2015 | 2,500,000 | 2,500 | 22,500 | 25,000 | |
Net Loss, December 31, 2015 | $ (586,441) | $ (586,441) | |||
Balance at Dec. 31, 2015 | 541,000,000 | 541,000 | 2,440,709 | (3,210,737) | (229,028) |
Condensed Consolidated Stateme6
Condensed Consolidated Statement of Cash Flows (Audited) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Cash flows from operating activities | ||
Net loss | $ (586,441) | $ (288,750) |
Non-cash expenses: | ||
Depreciation | 0 | 21,132 |
Stock based compensation to consultants | 286,200 | 45,750 |
Impairment of intangible asset | 0 | 210,000 |
Gain from disposal of property and equipment | 0 | (7,000) |
Changes in operating assets and liabilities: | ||
(Increase) decrease in inventory | (29,675) | 0 |
(Increase) decrease in accounts receivable | (2,184) | 0 |
(Increase) decrease in prepaid expenses and other current asets | (74,428) | (70,447) |
(Increase) decrease in other assets | (15) | (20) |
(Increase) decrease in bank overdraft | 0 | 0 |
Increase (decrease) in accounts payable | (13,212) | (7,967) |
Increase (decrease) in accrued expenses and other current liabilities | 860 | (236,577) |
Cash used by operating activities-continuing operations | (418,895) | (333,879) |
Cash provided (used) by operating activities-discontinued operations | 46,845 | 1,343 |
Net cash used by operating activities | (372,050) | (332,536) |
Cash flows from investing activities | ||
Disposal of fixed assets from discontinued operations | 0 | 55,000 |
Net cash used by by investing activities | 0 | 55,000 |
Cash flows from financing activities | ||
Related parties liabilities | 168,840 | 272,917 |
Stock issuance | 202,500 | 0 |
Repayments | 0 | (5,000) |
Net cash provided by financing activities | 371,340 | 267,917 |
Increase in cash | (711) | (9,619) |
Cash at beginning of period | 2,894 | 12,513 |
Cash at end of period | 2,183 | 2,894 |
Significant non-cash investing and financing activities: | ||
Stock issuance for acquisition of intangible assets | 0 | 210,000 |
Stock issuance for due to related parties | 0 | 477,067 |
Supplemental Cash Flow Information: | ||
Cash paid for interest | 3,213 | 2,812 |
Cash paid for income taxes | $ 800 | $ 800 |
Nature of Business
Nature of Business | 12 Months Ended |
Dec. 31, 2015 | |
Nature of Business | |
Nature of Operations | Note 1 Nature of Business Therapeutic Solutions International, Inc. (the Company) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation organized September 21, 2010 (Splint). Splint is treated as the accounting acquirer in the accompanying financial statements. Until April 28, 2014 the Company sold (directly and through distributors and sublicensees), in non-US countries, plastic intraoral devices known as Anterior Midpoint Stop Appliances (AMPSA Products) . On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated. The ostensible reason Mr. Jaczko gave was our failure to make certain unspecified payments due under the license agreement to his clients. We disputed the termination, but believed that the costs involved with litigating the termination of the New License was not in the best interest of the Company and its shareholders. Therefore, the Company moved in a new direction. Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) ones immune system. Activating ones immune system is now a well-accepted method to cure certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. On the other hand, inhibiting ones immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The following outlines our relationships and divisions to focus on each of these programs: Nutraceutical Division ® ® OmniBiome, Inc., On November 18, 2015 the Company licensed to OmniBiome, Inc. certain intellectually property. The License agreement in its entirety may be read as an exhibit filed with Form 8K: https://www.sec.gov/Archives/edgar/data/1419051/000107878215001890/f8k111715_ex10z1.htm Licensed Patent Rights: Shall mean: a. Patent Application Serial No. 62/213260 filed 9-02-2015 by Licensor. b. Patent Application Serial No. 62/219020 filed 9-15-2015 by Licensor. c. Patent Application Serial No. 62/232722 filed 9-25-2015 by Licensor. 1. Initial Payment and Royalty Rate. For the licensed herein granted: (a) Licensee agrees to pay a sign-up fee of $ 50,000.00. As of October 25, 2016 this fee has not been paid. OmniBiome did not have any operations as of December 31, 2015. (b) Licensee shall pay on earned royalty of Five Percent (5 %) of Licensees Gross Sales of Products and fifty percent (50%) of the sublicensing receipts. (c) Licensee shall pay an annual minimum royalty fee of Fifteen Thousand Dollars ($15,000.00) for each licensed Product. On December 4, 2015 the Company licensed to OmniBiome, Inc. certain intellectually property. The License agreement in its entirety may be read as an exhibit filed with Form 8K: https://www.sec.gov/Archives/edgar/data/1419051/000107878215001971/f8k120815_ex10z2.htm 1. Licensed Patent Rights: Shall mean: a. Patent Application Serial No. 62/194990 filed 7-21-2015 by Licensor. 1. Initial Payment and Royalty Rate. For the licensed herein granted: (a) Licensee agrees to pay a sign-up fee of $ 50,000.00. As of October 25, 2016 this fee has not been paid. (b) Licensee shall pay on earned royalty of Five Percent (5 %) of Licensees Gross Sales of Products and fifty percent (50%) of the sublicensing receipts. (c) Licensee shall pay an annual minimum royalty fee of Fifteen Thousand Dollars ($15,000.00) for each licensed Product. Current programs focus on the use of probiotics to prevent pre-term labor and on using probiotics to reverse periodontal disease. Mr. Dixon and Mr. Berg, of the Company, are also officers and Directors of Omni. As of October 25, 2016 TSI owns approximately 73.75% of the outstanding shares of Omni. Website: http://omnibiomeinc.com . |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2015 | |
Significant Accounting Policies: | |
Significant Accounting Policies | Note 2 Significant Accounting Policies Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2015 and 2014. Other assets include restricted cash of $10,000 that is used to secure a company credit card. Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 Intangibles Goodwill and Other. Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the year ended December 31, 2014, the Company recognized an impairment charge of $210,000 for intangible assets. Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" Accounting for Uncertainty in Income Taxes an Interpretation of FASB Statement No. 109. Going Concern The Company's financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses over the past years which have resulted in stockholders accumulated deficits of approximately $3.2 million at December 31 2015. These conditions raise uncertainty about the Companys ability to continue as a going concern. The Companys ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Share Based Expenses ASC 718 "Compensation - Stock Compensation," The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 "Equity-Based Payments to Non-Employees," "Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services". Recently Implemented Standards The Company has implemented all new accounting pronouncements that are in effect that may impact its financial statements and does not believe that there are any new accounting pronouncements that have been issued that might have a material impact on its financial statements. |
Restricted Cash
Restricted Cash | 12 Months Ended |
Dec. 31, 2015 | |
Restricted Cash: | |
Restricted Cash | Note 3 Restricted Cash Other non-current asset is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2017, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011. |
Equipment
Equipment | 12 Months Ended |
Dec. 31, 2015 | |
Equipment | |
Equipment | Note 4 Equipment The cost and accumulated depreciation of fixed assets and equipment at December 31, 2014 and 2013 are summarized below: December 31, 2015 December 31, 2014 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ - Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Depreciation expenses for the years ended December 31, 2015 and 2014 were $0 and $21,132, respectively. |
License Agreements
License Agreements | 12 Months Ended |
Dec. 31, 2015 | |
License Agreements | |
License Agreements | Note 5 License Agreements The Company had a New License Agreement for the period from August 24, 2012 to December 31, 2012, an exclusive worldwide license with a 30% royalty on net sales (subject to reduction under certain conditions). Also, the New License Agreement granted the Company, for the period from January 1, 2013 forward, a royalty-free nonexclusive worldwide license to make and sell certain products, but excluding the United States market. On April 28, 2014, the Company received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated |
Intangible Asset
Intangible Asset | 12 Months Ended |
Dec. 31, 2015 | |
Intangible Asset: | |
Intangible Asset | Note 6 - Intangible Asset On December 9, 2014 the Company contractually obtained the rights, title and interest in and to proprietary formulations for two nutritional supplement products known under the trade names: (a) T-Rx; and, (b) Vital Female; and, (ii) the purchase of all legal right, title and interest, in and to intellectual property including, but not limited to, Innovatives nutritional supplement product known under the trade name: Projuvenol. The Company issued 100,000,000 shares for this rights, title and interest. The fair value of the 100,000,000 shares of common stock of $210,000 was recorded as an intangible asset. On December 31, 2014, the Company performed an impairment test on the intellectual property. The Company recorded impairment of $210,000. |
Notes Payable-related party
Notes Payable-related party | 12 Months Ended |
Dec. 31, 2015 | |
Notes Payable-related party: | |
Notes Payable-related party | Note 7 Notes Payable-related party As of December 31, 2015 and 2015, the Notes Payable are as the following: December 31, 2015 Issued Original Total Interest Noteholder Date amounts Addition Repayment Interest Balance Rate Gerry Berg 12/18/2015 80,000 - - - 80,000 8% Barry Glassman 1/14/2013 15,000 - - 1,147 13,574 10% Timothy Dixon 1/16/2013 19,000 - 2,000 1,368 13,595 9.75% Timothy Dixon 1/16/2013 15,000 7,300 - 1,190 20,069 10% Timothy Dixon 12/18/2015 80,000 - - - 80,000 8% December 31, 2014 Issued Original Total Interest Noteholder Date amounts Addition Repayment Interest Balance Rate Barry Glassman 1/14/2013 15,000 - 3,000 1,173 12,427 8% Timothy Dixon 1/16/2013 19,000 4,000 5,005 1,540 15,946 9.75% Timothy Dixon 1/16/2013 15,000 - 6,000 1,141 11,578 10% |
Equity Transactions
Equity Transactions | 12 Months Ended |
Dec. 31, 2015 | |
Equity Transactions | |
Equity Transactions | Note 8 Equity Transactions Preferred Stock The Company is authorized to issue 5,000,000 shares of $.001 par value preferred stock. The Company has not issued any preferred stock. Common Stock As of July 27, 2016, the Company is authorized to issue 990,000,000 shares of $.001 par value common stock. All shares have equal voting rights, are non-assessable, and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 2,500,000 shares of common stock, valued at $.004 per share, for consulting services. On March 31, 2014, we issued 2,000,000 shares of common stock, valued at $.0035 per share, for consulting services. On March 31, 2014, we issued 5,000,000 shares of common stock, valued at $.004 per share, for legal services. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On December 9, 2014, we issued 100,000,000 shares of common stock, valued at $.0021 per share, in regard to a Material Definitive Agreement (Form 8-K filed on December 10, 2014). On March 27, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On February 27, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 1, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On April 17, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On June 1, 2015, we issued 3,000,000 shares of common stock, valued at $.0026 per share, for consulting services. On June 1, 2015, we issued 7,000,000 shares of common stock, valued at $.0025 per share, for legal services On June 8, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On July 15, 2015, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On August 31, 2015, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On September 25, 2015, we issued 10,000,000 shares of common stock, valued at $.0046 per share, for consulting services. On October 1, 2015, we issued 23,000,000 shares of common stock, valued at $.0063 per share, for consulting services. On October 13, 2015, we issued 2,500,000 shares of common stock, valued at $.0060 per share, for consulting services. On October 14, 2015, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On October 16, 2015, we issued 4,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On November 9, 2015, we issued 3,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On November 23, 2015, we issued 20,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On November 30, 2015, we issued 2,500,000 shares of common stock, valued at $.01 per share, for legal services. On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.0004 per share, for consulting services. On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services. On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.003 per share, for consulting services. On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016). On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.004 per share, for consulting services. On March 21, 2016, we issued 100,800,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On May 2, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement and 1,000,000 shares of common stock, valued at $.0053 per share, for consulting services. On May 26, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for consulting services. On May 26, 2016, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On May 31, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for legal services. On July 27, 2016, we filed with the Nevada Secretary of State a Certificate of Amendment to Articles of Incorporation to effect an amendment (the Amendment) changing the number of authorized shares of our common stock to 990,000,000. On September 16, 2016, we issued 12,500,000 shares of common stock, valued at $.004 per share, for an investment in the Companys Private Placement. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2015 | |
Related Party Transactions: | |
Related Party Transactions | Note 9 Related Party Transactions On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On June 19, 2014, we issued 45,000,000 shares of common stock, valued at $.003 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500, shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,476,435shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 26,562,500 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 21,250,000 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. On September 30, 2014, we issued 7,682,165 shares of common stock, valued at $.002 per share, to an officer of the Company for a conversion of notes payable for accrued wages. As of December 31, 2015, the Company has advanced approximately $117,900 to the officers of the company. Additionally the officers of the Company waived their monthly salary accrual from July 1, 2014 to December 31, 2014. The Company accrued officers salary of $20,384 in 2015 ($43,675 in 2014). On October 18, 2016, we issued 40,000,000 shares valued at $.0045 to the officers and directors of the Company for services. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2015 | |
Income Taxes | |
Income Tax Disclosure | Note 10 Income Taxes The Company has net operating losses carried forward of $2,270,802 (2014 $2,043,048) available to offset taxable income in future years which expire beginning in fiscal 2031. The Company is subject to United States federal and state income taxes at an approximate rate of 45%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Companys income tax expense as reported is as follows: December 31, 2015 $ December 31, 2014 $ Net loss before income taxes per financial statements (586,441) (288,750) Income tax rate 45% 45% Income tax recovery (263,898) (123,619) Permanent differences 88,616 6,318 Change in valuation allowance 175,282 117,301 Provision for income taxes The significant components of deferred income tax assets and liabilities at December 31, 2015 and 2014 are as follows: December 31, 2015 $ December 31, 2014 $ Net operating loss carry-forward 1,021,679 846,397 Valuation allowance (1,021,679) (846,397) Net deferred income tax asset |
Discontinued Operation
Discontinued Operation | 12 Months Ended |
Dec. 31, 2015 | |
Discontinued Operation: | |
Discontinued Operation | Note 11 Discontinued Operation On April 28, 2014, we received a letter from Mr. J. Christopher Jaczko, a lawyer with the Procopio law firm in San Diego who represents Boyd Research, Inc. and related parties. In his letter, Mr. Jaczko notified us that our license to use the international patents for our AMPSA device, pursuant to our license agreement with his clients effective January 1, 2013, was terminated. The following are the summarized results of discontinued operations for the years ended December 31, 2015 and 2014 and the Balance Sheet as of December 31, 2015 and 2014: For the Year Ended December 31, 2015 For the Year Ended December 31, 2014 Net international revenues $ - $ 268,892 Cost of goods sold - (26,798) Selling expenses - (6,525) Bad debt (9,770) - Obsolete Inventory (4,052) - Royalties - 13,433 $ (13,822) $ 249,002 December 31, 2015 December 31, 2014 Assets Accounts Receivable, net $ - $ 46,895 Total assets of discontinued operations $ - $ 46,895 |
Litigation
Litigation | 12 Months Ended |
Dec. 31, 2015 | |
Litigation: | |
Litigation | Note 12 Litigation The Company previously reported, on April 29, 2013 a former employee of the Company, Reid Jilek, sued the Company, its two directors and its three officers in San Diego County (California) Superior Court for breach of contract, retaliation, constructive discharge, failure to pay wages, failure to reimburse, conversion and fraudulent inducement. The complaint related to his employment agreement with the Company and his resignation which was effective in January 2013. The trial was held in September 2014. On September 26, 2014 the Court ruled in favor of the Company and against all of Jilek's claims, and ruled that the Company was the prevailing party, and therefore was entitled to recover its attorneys fees and costs from Jilek. The Company did not prevail in its cross-claims against Jilek. Jilek's claims against the Companys directors and officers had previously been dismissed. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2015 | |
Subsequent Events: | |
Subsequent Events | Note 13 Subsequent Events On January 4, 2016, we issued 2,500,000 shares of common stock, valued at $.0025 per share, for consulting services. On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0035 per share, for consulting services. On February 1, 2016, we issued 2,500,000 shares of common stock, valued at $.003 per share, for consulting services. On February 5, 2016, we issued 8,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On February 22, 2016, we issued 5,451,000 shares of common stock, valued at $.003 per share, in regard to a License Agreement (Form 8-K filed on February 25, 2016). On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.0025 per share, for consulting services. On March 21, 2016, we issued 100,800,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On May 2, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement and 1,000,000 shares of common stock, valued at $.0053 per share, for consulting services. On May 26, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for consulting services. On May 26, 2016, we issued 2,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Companys Private Placement. On May 31, 2016, we issued 2,500,000 shares of common stock, valued at $.0066 per share, for legal services. On January 21, 2016, our Board of Directors elected Thomas E. Ichim, Ph.D, to fill a vacant seat on our Board of Directors. On February 05, 2016, Therapeutic Solutions International, Inc. licensed certain intellectual property to MolecuVax, Inc., a wholly owned subsidiary of Therapeutic Solutions International, Inc., Application No. 62/258,007 titled Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer. On April 27, 2016, the United States Patent and Trademark Office (the USPTO) accepted U.S. Application No. 62/327756 titled Augmentation Of Stem Cell Activity Using Pterostilbene And Compositions Containing Pterostilbene. On July 27, 2016, we filed with the Nevada Secretary of State a Certificate of Amendment to Articles of Incorporation to effect an amendment (the Amendment) changing the number of authorized shares of our common stock to 990,000,000. On August 22, 2016, the Board of Directors deemed it to be in the best interest of the Company to affect a reverse stock-split of its common stock of one (1) new common share for each two (2) old common shares of stock, subject to approval by a majority of shareholders. If sufficient votes are not obtained from a majority of shareholders, this action will become cancelled as of October 31, 2016. On September 16, 2016, we issued 12,500,000 shares of common stock, valued at $.004 per share, for an investment in the Companys Private Placement. The Company previously announced that MolecuVax, Inc. (MVAX) was a partially-owned subsidiary of TSOI. On September 30, 2016, Mr. Gerry Berg, and Mr. Timothy Dixon resigned as Officers and Directors of MVAX and cancelled any and all equity in MVAX and have asserted certain contractual rights of our licensed patent to MVAX dated February 5 th The Company previously announced that TSOI held an equity stake in Capo Therapeutics, Inc. (CAPO). On September 30, 2016, Mr. Gerry Berg, and Mr. Timothy Dixon resigned as Officers and Directors of CAPO and cancelled any and all equity in CAPO. Our departure and subsequent cancellation of stock was due to an attempt at a hostile take-over of the Board of Directors of CAPO by other board members. On October 18, 2016, we issued 40,000,000 shares valued at $.0045 to the officers and directors of the Company for services, and 5,000,000 shares valued at $.0045 for consulting services. |
Accounting Policies (Policies)
Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies: | |
Estimates | Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Cash, Policy | Cash For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of December 31, 2015 and 2014. Other assets include restricted cash of $10,000 that is used to secure a company credit card. |
Depreciation and Amortization, Policy | Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. |
Intangible Assets, Policy | Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 Intangibles Goodwill and Other. |
Long-lived Assets | Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the year ended December 31, 2014, the Company recognized an impairment charge of $210,000 for intangible assets. |
Income Taxes, Policy | Income Taxes "Income Taxes," "Accounting for Income Taxes" Accounting for Uncertainty in Income Taxes an Interpretation of FASB Statement No. 109. |
Going Concern | Going Concern The Company's financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses over the past years which have resulted in stockholders accumulated deficits of approximately $3.2 million at December 31 2015. These conditions raise uncertainty about the Companys ability to continue as a going concern. The Companys ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. |
Share Based Expenses | Share Based Expenses ASC 718 "Compensation - Stock Compensation," The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 "Equity-Based Payments to Non-Employees," "Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services". |
Recently Implemented Standards | Recently Implemented Standards The Company has implemented all new accounting pronouncements that are in effect that may impact its financial statements and does not believe that there are any new accounting pronouncements that have been issued that might have a material impact on its financial statements. |
Schedule of Cost and accumulate
Schedule of Cost and accumulated depreciation of fixed assets and equipment (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Cost and accumulated depreciation of fixed assets and equipment: | |
Schedule of Cost and accumulated depreciation of fixed assets and equipment | The cost and accumulated depreciation of fixed assets and equipment at December 31, 2014 and 2013 are summarized below: December 31, 2015 December 31, 2014 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ - |
Schedule of Notes Payable-relat
Schedule of Notes Payable-related party (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Notes Payable-related party | |
Schedule of Notes Payable-related party | As of December 31, 2015 and 2015, the Notes Payable are as the following: December 31, 2015 Issued Original Total Interest Noteholder Date amounts Addition Repayment Interest Balance Rate Gerry Berg 12/18/2015 80,000 - - - 80,000 8% Barry Glassman 1/14/2013 15,000 - - 1,147 13,574 10% Timothy Dixon 1/16/2013 19,000 - 2,000 1,368 13,595 9.75% Timothy Dixon 1/16/2013 15,000 7,300 - 1,190 20,069 10% Timothy Dixon 12/18/2015 80,000 - - - 80,000 8% December 31, 2014 Issued Original Total Interest Noteholder Date amounts Addition Repayment Interest Balance Rate Barry Glassman 1/14/2013 15,000 - 3,000 1,173 12,427 8% Timothy Dixon 1/16/2013 19,000 4,000 5,005 1,540 15,946 9.75% Timothy Dixon 1/16/2013 15,000 - 6,000 1,141 11,578 10% |
Schedule of Income Taxes (Table
Schedule of Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Income Taxes | |
Schedule of Effective Income Tax Rate Reconciliation | The Company is subject to United States federal and state income taxes at an approximate rate of 45%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Companys income tax expense as reported is as follows: December 31, 2015 $ December 31, 2014 $ Net loss before income taxes per financial statements (586,441) (288,750) Income tax rate 45% 45% Income tax recovery (263,898) (123,619) Permanent differences 88,616 6,318 Change in valuation allowance 175,282 117,301 Provision for income taxes |
Schedule of Deferred Tax Assets and Liabilities | The significant components of deferred income tax assets and liabilities at December 31, 2015 and 2014 are as follows: December 31, 2015 $ December 31, 2014 $ Net operating loss carry-forward 1,021,679 846,397 Valuation allowance (1,021,679) (846,397) Net deferred income tax asset |
Schedule of Summary of Results
Schedule of Summary of Results of Discontinued Operations (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Summary of Results of Discontinued Operations | |
Schedule of Summary of Results of Discontinued Operations | The following are the summarized results of discontinued operations for the years ended December 31, 2015 and 2014 and the Balance Sheet as of December 31, 2015 and 2014: For the Year Ended December 31, 2015 For the Year Ended December 31, 2014 Net international revenues $ - $ 268,892 Cost of goods sold - (26,798) Selling expenses - (6,525) Bad debt (9,770) - Obsolete Inventory (4,052) - Royalties - 13,433 $ (13,822) $ 249,002 December 31, 2015 December 31, 2014 Assets Accounts Receivable, net $ - $ 46,895 Total assets of discontinued operations $ - $ 46,895 |
Cash (Details)
Cash (Details) | Dec. 31, 2015USD ($) |
Cash Details | |
Other assets include restricted cash | $ 10,000 |
Long-lived Assets (Details)
Long-lived Assets (Details) | 12 Months Ended |
Dec. 31, 2014USD ($) | |
Long-lived Assets Details | |
Company recognized an impairment charge of for intangible assets | $ 210,000 |
Going Concern (Details)
Going Concern (Details) | Dec. 31, 2015USD ($) |
Going Concern Details | |
Accumulated deficit (approx) | $ 3,200,000 |
Restricted Cash (Details)
Restricted Cash (Details) | Dec. 31, 2015USD ($) |
Restricted Cash Details | |
Other non-current asset certificate of deposit | $ 10,000 |
Annual interest rate | 0.60% |
Equipment (Details)
Equipment (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Equipment Consists Of the Following: | ||
Computer Hardware | $ 10,747 | $ 10,747 |
Office Furniture and Equipment | 3,639 | 3,639 |
Shipping and Other Equipment | 1,575 | 1,575 |
Total | 15,961 | 15,961 |
Accumulated Depreciation | $ (15,961) | (15,961) |
Property and Equipment, net | $ 0 |
Equipment - Depreciation (Detai
Equipment - Depreciation (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Equipment - Depreciation Details | ||
Depreciation expense | $ 0 | $ 21,132 |
License (Details)
License (Details) | Dec. 31, 2012 |
License Agreements Consists Of the Following: | |
New License Agreement for an exclusive worldwide license with a royalty on net sales percent | 30.00% |
Intangible Asset (Details)
Intangible Asset (Details) - USD ($) | Dec. 31, 2014 | Dec. 09, 2014 |
Intangible Asset Details | ||
Issued shares for the rights, title and interest | 100,000,000 | |
Fair value of the shares of common stock recorded as intangible assets | $ 210,000 | |
Impairment of intangible assets | $ 210,000 |
Notes Payable-related party Ger
Notes Payable-related party Gerry Berg (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Notes Payable-related party Gerry Berg Details | |
Gerry Berg Issued Date | Dec. 18, 2015 |
Gerry Berg Original amounts | $ 80,000 |
Gerry Berg Total Balance | $ 80,000 |
Gerry Berg Interest Rate | 8.00% |
Notes Payable-related party Bar
Notes Payable-related party Barry Glassman (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Notes Payable-related party Barry Glassman Details | ||
Barry Glassman Issued Date | Jan. 14, 2013 | Jan. 14, 2013 |
Barry Glassman Original amounts | $ 15,000 | $ 15,000 |
Barry Glassman Repayment | 3,000 | |
Barry Glassman Interest | 1,173 | |
Barry Glassman Total Balance | $ 13,574 | $ 12,427 |
Barry Glassman Interest Rate | 10.00% | 8.00% |
Notes Payable-related party Tim
Notes Payable-related party Timothy Dixon 1 (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Notes Payable-related party Timothy Dixon 1 Details | ||
Timothy Dixon 1 Issued Date | Jan. 16, 2013 | Jan. 16, 2013 |
Timothy Dixon 1 Original amounts | $ 19,000 | $ 19,000 |
Timothy Dixon 1 Addition | 4,000 | |
Timothy Dixon 1 Repayment | 2,000 | 5,005 |
Timothy Dixon 1 Interest | 1,368 | 1,540 |
Timothy Dixon 1 Total Balance | $ 13,595 | $ 15,946 |
Timothy Dixon 1 Interest Rate | 9.75% | 9.75% |
Notes Payable-related party T36
Notes Payable-related party Timothy Dixon 2 (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Notes Payable-related party Timothy Dixon 2 Details | ||
Timothy Dixon 2 Issued Date | Jan. 16, 2013 | Jan. 16, 2013 |
Timothy Dixon 2 Original amounts | $ 15,000 | $ 15,000 |
Timothy Dixon 2 Addition | 7,300 | |
Timothy Dixon 2 Repayment | 6,000 | |
Timothy Dixon 2 Interest | 1,190 | 1,141 |
Timothy Dixon 2 Total Balance | $ 20,069 | $ 11,578 |
Timothy Dixon 2 Interest Rate | 10.00% | 10.00% |
Notes Payable-related party T37
Notes Payable-related party Timothy Dixon 3 (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Notes Payable-related party Timothy Dixon 3 Details | |
Timothy Dixon 3 Issued Date | Dec. 18, 2015 |
Timothy Dixon 3 Original amounts | $ 80,000 |
Timothy Dixon 3 Total Balance | $ 80,000 |
Timothy Dixon 3 Interest Rate | 10.00% |
Capital Stock Transactions (Det
Capital Stock Transactions (Details) | Dec. 31, 2015$ / sharesshares |
PREFERRED STOCK: | |
Preferred Stock, authorized shares | shares | 5,000,000 |
Preferred Stock par value | $ / shares | $ 0.001 |
COMMON STOCK: | |
Common Stock authorized shares | shares | 990,000,000 |
Common Stock par value | $ / shares | $ 0.001 |
Voting rights | 50.00% |
Capital Stock Transactions Duri
Capital Stock Transactions During 2014 (Details) - $ / shares | Dec. 09, 2014 | Sep. 30, 2014 | Jun. 19, 2014 | Mar. 31, 2014 |
Capital Stock Transactions During 2014 Details | ||||
Issued shares of common stock for consulting services | 2,500,000 | |||
Issued shares of common stockfor consulting services per share | $ 0.0035 | |||
Issued shares of common stock for consulting services | 2,500,000 | |||
Issued shares of common stockfor consulting services per share | $ 0.004 | |||
Issued shares of common stock for consulting services | 2,000,000 | |||
Issued shares of common stockfor consulting services per share | $ 0.0035 | |||
Issued shares of common stock for legal services | 5,000,000 | |||
Issued shares of common stock for legal services per share | $ 0.004 | |||
Issued shares of common stock for a conversion of notes payable for accrued wages | 26,562,500 | 45,000,000 | ||
Issued shares of common stock for a conversion of notes payable for accrued wages per share | $ 0.002 | $ 0.003 | ||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages | 21,476,435 | 45,000,000 | ||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share | $ 0.002 | $ 0.003 | ||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages | 26,562,500 | |||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share | $ 0.002 | |||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages | 21,250,000 | |||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share | $ 0.002 | |||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages | 7,682,165 | |||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share | $ 0.002 | |||
Issued shares of common stockin regard to a Material Definitive Agreement | 100,000,000 | |||
Issued shares of common stockin regard to a Material Definitive Agreement per share | $ 0.0021 |
Capital Stock Transactions Du40
Capital Stock Transactions During 2015 (Details) - $ / shares | Nov. 30, 2015 | Nov. 23, 2015 | Nov. 09, 2015 | Oct. 13, 2015 | Oct. 01, 2015 | Sep. 25, 2015 | Aug. 31, 2015 | Jul. 15, 2015 | Jun. 08, 2015 | Jun. 01, 2015 | Apr. 17, 2015 | Apr. 01, 2015 | Mar. 27, 2015 | Feb. 27, 2015 |
Capital Stock Transactions During 2015 | ||||||||||||||
Shares of common stock for consulting services | 5,000,000 | 2,500,000 | 23,000,000 | 3,000,000 | 10,000,000 | |||||||||
Shares of common stock for consulting services per share | $ 0.0025 | $ 0.006 | $ 0.0063 | $ 0.0026 | $ 0.0025 | |||||||||
Shares of common stock for Private Placement | 2,000,000 | 3,000,000 | 4,000,000 | 2,000,000 | 10,000,000 | 10,000,000 | 1,000,000 | 1,000,000 | 20,000,000 | 20,000,000 | 20,000,000 | |||
Shares of common stock for Private Placement per share | $ 0.0025 | $ 0.0025 | $ 0.0025 | $ 0.0025 | $ 0.0046 | $ 0.0025 | $ 0.0025 | $ 0.0025 | $ 0.0025 | $ 0.0025 | $ 0.0025 | |||
Shares of common stock for legal services | 2,500,000 | 7,000,000 | ||||||||||||
Shares of common stock for legal services per share | $ 0.01 | $ 0.0025 |
Capital Stock Transactions Du41
Capital Stock Transactions During 2016 (Details) - $ / shares | Oct. 18, 2016 | Sep. 16, 2016 | Jul. 27, 2016 | May 31, 2016 | May 26, 2016 | May 02, 2016 | Mar. 21, 2016 | Mar. 07, 2016 | Feb. 26, 2016 | Feb. 22, 2016 | Feb. 05, 2016 | Feb. 01, 2016 | Jan. 22, 2016 | Jan. 04, 2016 |
Capital Stock Transactions During 2016 | ||||||||||||||
Issued shares of common stock for consulting services | 5,000,000 | 2,500,000 | 1,000,000 | 10,000,000 | 2,500,000 | 2,500,000 | 2,500,000 | |||||||
Issued shares of common stockfor consulting services per share | $ 0.0045 | $ 0.0066 | $ 0.0025 | $ 0.004 | $ 0.003 | $ 0.0035 | $ 0.0004 | |||||||
Issued shares of common stock for for an investment in Private Placement | 12,500,000 | 2,000,000 | 1,000,000 | 100,800,000 | 1,000,000 | 8,000,000 | ||||||||
Issued shares of common stock for an investment in Private Placement per share | $ 0.004 | $ 0.0025 | $ 0.0053 | $ 0.0025 | $ 0.0025 | $ 0.0025 | ||||||||
Issued shares of common stock in regard to a License Agreement | 5,451,000 | |||||||||||||
Issued shares of common stock in regard to a License Agreement per share | $ 0.003 | |||||||||||||
Issued shares of common stock for legal services | 2,500,000 | |||||||||||||
Issued shares of common stockfor legal services per share | $ 0.0066 | |||||||||||||
Authorized shares of our common stock | 990,000,000 | |||||||||||||
Issued shares of common stock to the officers and directors | 40,000,000 | |||||||||||||
Issued shares of common stock to the officers and directors per share | $ 0.0045 |
Related Party Transactions Agre
Related Party Transactions Agreement (Details) - USD ($) | Oct. 18, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 19, 2014 |
Related Party Transactions Agreement: | |||||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages | 26,562,500 | 45,000,000 | |||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share | $ 0.002 | $ 0.003 | |||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages | 21,476,435 | 45,000,000 | |||
Issued shares of common stock to an officer for a conversion of notes payable for accrued wages per share | $ 0.002 | $ 0.003 | |||
Shares of common stock to an officer for a conversion of notes payable for accrued wages | 26,562,500 | ||||
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share | $ 0.002 | ||||
Shares of common stock to an officer for a conversion of notes payable for accrued wages | 21,250,000 | ||||
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share | $ 0.002 | ||||
Shares of common stock to an officer for a conversion of notes payable for accrued wages | 7,682,165 | ||||
Shares of common stock to an officer for a conversion of notes payable for accrued wages valued at per share | $ 0.002 | ||||
Advanced to the officers | $ 117,900 | ||||
Accrued officers salary | $ 20,384 | $ 43,675 | |||
Issued shares of common stock to the officers and directors of the Company for services | 40,000,000 | ||||
Issued shares of common stock to the officers and directors of the Company for services per share | $ 0.0045 |
Income Taxes (Narrative) (Detai
Income Taxes (Narrative) (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Income Taxes Narrative Details | ||
Net operating losses carried forward | $ 2,270,802 | $ 2,043,048 |
Income tax expense as reported
Income tax expense as reported is as follows (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Income tax expense as reported is as follows details | ||
Net loss before income taxes per financial statements | $ (586,441) | $ (288,750) |
Income tax rate | 45.00% | 45.00% |
Income tax recovery | $ (263,898) | $ (123,619) |
Permanent differences | 88,616 | 6,318 |
Change in valuation allowance | 175,282 | $ 117,301 |
Provision for income taxes | $ 0 |
Components of deferred income t
Components of deferred income tax assets and liabilities (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Components of deferred income tax assets and liabilities: | ||
Net operating loss carry-forward | $ 1,021,679 | $ 846,397 |
Valuation allowance | (1,021,679) | $ (846,397) |
Net deferred income tax asset | $ 0 |
Results of discontinued operati
Results of discontinued operations (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Results of discontinued operations details | ||
Net revenues discontinued operations | $ 268,892 | |
Cost of goods sold discontinued operations | (26,798) | |
Selling expenses discontinued operations | (6,525) | |
Bad debt discontinued operations | $ (9,770) | |
Obsolete inventory discontinued operations | (4,052) | |
Royalties discontinued operations | 13,433 | |
Total discontinued operations | $ (13,822) | 249,002 |
Assets discontinued operations | ||
Accounts Receivable, net discontinued operations | 46,895 | |
Total assets of discontinued operations | $ 46,895 |
Subsequent Events During 2016 (
Subsequent Events During 2016 (Details) - $ / shares | Oct. 18, 2016 | Sep. 16, 2016 | Jul. 27, 2016 | May 31, 2016 | May 26, 2016 | May 02, 2016 | Mar. 21, 2016 | Mar. 07, 2016 | Feb. 26, 2016 | Feb. 22, 2016 | Feb. 05, 2016 | Feb. 01, 2016 | Jan. 22, 2016 | Jan. 04, 2016 |
Subsequent Events During 2016 Details | ||||||||||||||
Issued shares of common stock for consulting services | 5,000,000 | 2,500,000 | 1,000,000 | 10,000,000 | 2,500,000 | 2,500,000 | 2,500,000 | |||||||
Issued shares of common stockfor consulting services per share | $ 0.0045 | $ 0.0066 | $ 0.0025 | $ 0.0025 | $ 0.003 | $ 0.0035 | $ 0.0025 | |||||||
Issued shares of common stock for for an investment in Private Placement | 12,500,000 | 2,000,000 | 1,000,000 | 100,800,000 | 1,000,000 | 8,000,000 | ||||||||
Issued shares of common stock for an investment in Private Placement per share | $ 0.004 | $ 0.0025 | $ 0.0053 | $ 0.0025 | $ 0.0025 | $ 0.0025 | ||||||||
Issued shares of common stock in regard to a License Agreement | 5,451,000 | |||||||||||||
Issued shares of common stock in regard to a License Agreement per share | $ 0.003 | |||||||||||||
Issued shares of common stock for legal services | 2,500,000 | |||||||||||||
Issued shares of common stockfor legal services per share | $ 0.0066 | |||||||||||||
Authorized shares of our common stock | 990,000,000 | |||||||||||||
Issued shares of common stock to the officers and directors | 40,000,000 | |||||||||||||
Issued shares of common stock to the officers and directors per share | $ 0.0045 |